Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia

Cytokine

Volumn 62, Issue 2, 2013, Pages 322-326

  Stepan, Holger ^a   Kley, Karoline ^a   Hindricks, Janka ^a   Kralisch, Susan ^a,b   Jank, Alexander ^a   Schaarschmidt, Wiebke ^a   Schrey, Susanne ^a   Ebert, Thomas ^a   Lössner, Ulrike ^a,b   Kratzsch, Jürgen ^a   Blüher, Matthias ^a   Stumvoll, Michael ^a   Richter, Judit ^a,b   Fasshauer, Mathias ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Adipokine; FGF 21; Insulin resistance; Obesity; Preeclampsia

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HIGH DENSITY LIPOPROTEIN RECEPTOR; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BIRTH WEIGHT; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; FEMALE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; UPREGULATION; BLOOD; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; PREGNANCY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, LDL; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; GLUCOSE; HUMANS; INFLAMMATION; KIDNEY; KIDNEY FUNCTION TESTS; LIPID METABOLISM; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; TRIGLYCERIDES;

EID: 84876812580     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.02.019     Document Type: Article

References (37)

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
2. Stepan H., Geide A., Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med 2004, 351:2241-2242.
3. Stepan H., Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006, 354:1857-1858.
4. Stepan H., Walther T. Questionable role of the angiotensin II Receptor subtype 1 autoantibody in the pathogenesis of preeclampsia. Hypertension 2007, 50:e3.
5. Stepan H., Unversucht A., Wessel N., Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007, 49:818-824.
6. Poston L. Leptin and preeclampsia. Semin Reprod Med 2002, 20:131-138.
7. Jansson N., Greenwood S.L., Johansson B.R., Powell T.L., Jansson T. Leptin stimulates the activity of the system a amino acid transporter in human placental villous fragments. J Clin Endocrinol Metab 2003, 88:1205-1211.
8. Huppertz B., Abe E., Murthi P., Nafamatsu T., Szukiewicz D., Salafia C. Placental angiogenesis, maternal and fetal vessels - a workshop report. Placenta 2007, 28:S94-S96.
9. Conrad K.P., Miles T.M., Benyo D.F. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998, 40:102-111.
10. LaMarca B.B.D., Bennett W.A., Alexander B.T., Cockrell K., Granger J.P. Hypertension produced by reductions in uterine perfusion in the pregnant rat role of tumor necrosis factor-α. Hypertension 2005, 46:1022-1025.
11. Freeman D.J., McManus F., Brown E.A., Cherry L., Norrie J., Ramsay J.E., et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004, 44:708-714.
12. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
13. Wente W., Efanov A.M., Brenner M., Kharitonenkov A., Köster A., Sandusky G.E., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55:2470-2478.
14. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
15. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
16. Lundasen T., Hunt M.C., Nilsson L.M., Sanyal S., Angelin B., Alexson S.E., et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007, 360:437-440.
17. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
18. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
19. Mise H., Sagawa N., Matsumoto T., Yura S., Nanno H., Itoh H., et al. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. J Clin Endocrinol Metab 1998, 83:3225-3229.
20. Gifford R.W., et al. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22.
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
22. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
23. Fasshauer M., Waldeyer T., Seeger J., Schrey S., Ebert T., Kratzsch J., et al. Serum levels of the adipokine visfatin are increased in preeclampsia. Clin Endocrinol 2008, 69:69-73.
24. Fasshauer M., Waldeyer T., Seeger J., Schrey S., Ebert T., Kratzsch J., et al. Circulating high molecular weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. Eur J Endocrinol 2008, 158:197-201.
25. Fasshauer M., Seeger J., Waldeyer T., Schrey S., Ebert T., Kratzsch J., et al. Serum levels of the adipokine adipocyte fatty acid-binding protein are increased in preeclampsia. Am J Hypertens 2008, 21:582-586.
26. Stepan H., Philipp A., Reiche M., Klostermann K., Schrey S., Reisenbüchler C., et al. Serum levels of the adipokine lipocalin-2 are increased in preeclampsia. J Endocrinol Invest 2010, 33:629-632.
27. Stepan H., Philipp A., Roth I., Kralisch S., Jank A., Schaarschmidt W., et al. Serum levels of the adipokine chemerin are increased in preeclampsia during and 6months after pregnancy. Regul Pept 2011, 168:69-72.
28. Gorar S., Culha C., Uc Z.A., Dellal F.D., Serter R., Aral S., et al. Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol 2010, 26:819-826.
29. Stein S., Stepan H., Kratzsch J., Verlohren M., Verlohren H.J., Drynda K., et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010, 59:33-37.
30. McCarthy F.P., Drewlo S., Kingdom J., Johns E.J., Walsh S.K., Kenny L.C. Peroxisome proliferator-activated receptor-γ as a potential therapeutic target in the treatment of preeclampsia. Hypertension 2011, 58:280-286.
31. McCarthy F.P., Drewlo S., English F.A., Kingdom J., Johns E.J., Kenny L.C., et al. Evidence implicating peroxisome proliferator-activated receptor-γ in the pathogenesis of preeclampsia. Hypertension 2011, 58:882-887.
32. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
33. Lin Z., Wu Z., Yin X., Liu Y., Yan X., Lin S., et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010, 5:e15534.
34. Li H., Bao Y., Xu A., Pan X., Lu J., Wu H., et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in chinese subjects. J Clin Endocrinol Metab 2009, 94:2151-2156.
35. Eto K., Tumenbayar B., Nagashima S., Tazoe F., Miyamoto M., Takahashi M., et al. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract 2010, 89:52-57.
36. Stein S., Bachmann A., Lössner U., Kratzsch J., Blüher M., Stumvoll M., et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 2009, 32:126-128.
37. Mai K., Schwarz F., Bobbert T., Andres J., Assmann A., Pfeiffer A.F., et al. Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism 2011, 60:306-311.